DK0759935T3 - Rekombinant papillomavirus L1 - Google Patents

Rekombinant papillomavirus L1

Info

Publication number
DK0759935T3
DK0759935T3 DK95918467T DK95918467T DK0759935T3 DK 0759935 T3 DK0759935 T3 DK 0759935T3 DK 95918467 T DK95918467 T DK 95918467T DK 95918467 T DK95918467 T DK 95918467T DK 0759935 T3 DK0759935 T3 DK 0759935T3
Authority
DK
Denmark
Prior art keywords
papilloma virus
protein
recombinant
vlp
recombinant papillomavirus
Prior art date
Application number
DK95918467T
Other languages
English (en)
Inventor
Ian Frazer
Jian Zhou
Original Assignee
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Queensland filed Critical Univ Queensland
Application granted granted Critical
Publication of DK0759935T3 publication Critical patent/DK0759935T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK95918467T 1994-05-17 1995-05-17 Rekombinant papillomavirus L1 DK0759935T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM5667A AUPM566794A0 (en) 1994-05-17 1994-05-17 Process and product
PCT/AU1995/000292 WO1995031476A1 (en) 1994-05-17 1995-05-17 Recombinant papilloma virus l1

Publications (1)

Publication Number Publication Date
DK0759935T3 true DK0759935T3 (da) 2003-11-10

Family

ID=3780242

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95918467T DK0759935T3 (da) 1994-05-17 1995-05-17 Rekombinant papillomavirus L1

Country Status (13)

Country Link
US (1) US6013262A (da)
EP (2) EP1325957B1 (da)
JP (3) JPH10500295A (da)
KR (1) KR100384922B1 (da)
AT (2) ATE340859T1 (da)
AU (1) AUPM566794A0 (da)
CA (1) CA2190473C (da)
DE (2) DE69535249T2 (da)
DK (1) DK0759935T3 (da)
ES (2) ES2203640T3 (da)
NZ (1) NZ285339A (da)
PT (2) PT759935E (da)
WO (1) WO1995031476A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
SK147696A3 (en) * 1994-05-16 1997-08-06 Merck & Co Inc Isolated and purified protein of papillomavirus, a capside, a viral particle, pharmaceutical composition comprising its, a method of making them and their use
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
EE9900612A (et) * 1997-04-08 2000-08-15 Merck & Co., Inc. Inimese papilloomiviiruse stabiliseeritud preparaadid
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US6689366B1 (en) * 1998-12-17 2004-02-10 Merck & Co., Inc. Synthetic virus like particles with heterologous epitopes
WO2000035479A1 (en) * 1998-12-17 2000-06-22 Merck & Co., Inc. Synthetic virus-like particles with heterologous epitopes
ATE290013T1 (de) * 1998-12-23 2005-03-15 Merck & Co Inc Neutralsierungs-assay, das humane papillomavirus- ähnliche partikel verwendet
SI1150712T1 (sl) 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
KR100366608B1 (ko) * 2000-02-15 2003-01-09 마스터진(주) 형질전환 식물체로부터 생산된 재조합 인간 파필로마바이러스 백신
DE60137230D1 (de) * 2000-07-06 2009-02-12 Univ Georgetown Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
WO2002009645A2 (en) * 2000-08-01 2002-02-07 The Johns Hopkins University Intercellular transport protein linked to an antigen as a molecular vaccine
AU2001278117A1 (en) * 2000-08-03 2002-02-18 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
EP1549140A4 (en) * 2002-09-03 2009-04-29 Kentucky Bioproc Llc PRODUCTION OF PEPTIDES IN PLANTS IN THE FORM OF HYBRID VIRAL HULL PROTEINS
WO2004098526A2 (en) * 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
JP5020825B2 (ja) * 2004-12-08 2012-09-05 ジェン−プローブ・インコーポレーテッド 複数型のヒトパピローマウイルスに由来する核酸の検出
AU2005322960A1 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
JP2008528004A (ja) * 2005-01-26 2008-07-31 ザ ジョンズ ホプキンス ユニバーシティー 突然変異癌タンパク質抗原およびカルレティキュリンをコードするプラスミドを用いる抗癌ｄｎａワクチン
AU2006236905B2 (en) * 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
WO2008024844A2 (en) * 2006-08-22 2008-02-28 The Johns Hopkins University Anticancer combination therapies
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US20100003704A1 (en) * 2008-06-13 2010-01-07 Shuling Cheng IN SITU detection of early stages and late stages HPV infection
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
WO2008134935A1 (fr) 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Protéines 18 l1 de type papillomavirus humain tronqué
CN101293918B (zh) * 2007-04-29 2013-03-27 北京万泰生物药业股份有限公司 截短的人乳头瘤病毒16型l1蛋白
WO2008145021A1 (en) 2007-05-29 2008-12-04 Xiamen University A truncated l1 protein of human papillomavirus 6
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
EP2427763A4 (en) 2009-05-07 2013-08-21 Oncohealth Corp IDENTIFICATION OF HIGH GRADE OR CIN2 FOR DETECTION, MONITORING AND DIAGNOSIS, AT EARLY STAGES AND ADVANCED STAGES, OF HUMAN PAPILLOMAVIRUS (HPV) AND HPV ASSOCIATED CANCERS
CN102822672B (zh) 2010-01-08 2015-12-09 安科健康公司 用于诊断和筛选与hpv有关的癌症的高通量细胞基hpv免疫测定
US9376727B2 (en) 2010-05-25 2016-06-28 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically truncated probes
EP4141110A1 (en) 2020-04-24 2023-03-01 Obshchestvo S Ogranichennoy Otvetstvennost'yu "Ingenik" Method for producing particles of bacteriophages of the genus levivirus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0133123A1 (en) * 1983-07-25 1985-02-13 Mgi Pharma, Inc. Immunogens of papilloma viruses
DE122007000017I1 (de) * 1991-07-19 2007-07-26 Univ Queensland Impfstoffe gegen Papillomavirus
DE122007000099I1 (de) * 1992-06-25 2008-03-27 Papillomavirus vakzine
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
EP1588713B1 (en) * 1993-03-09 2010-12-22 The University Of Rochester Production of human papillomavirus HBV-11 capsid protein L1 and virus-like particles

Also Published As

Publication number Publication date
ATE245164T1 (de) 2003-08-15
ES2275965T3 (es) 2007-06-16
DE69535249D1 (de) 2006-11-09
JP3878197B2 (ja) 2007-02-07
CA2190473C (en) 2011-08-30
DE69531297T2 (de) 2004-05-27
WO1995031476A1 (en) 1995-11-23
JPH10500295A (ja) 1998-01-13
DE69535249T2 (de) 2007-05-10
KR100384922B1 (ko) 2003-08-21
JP2006321806A (ja) 2006-11-30
EP0759935A1 (en) 1997-03-05
EP1325957B1 (en) 2006-09-27
JP2006001936A (ja) 2006-01-05
DE69531297D1 (de) 2003-08-21
JP4016054B2 (ja) 2007-12-05
CA2190473A1 (en) 1995-11-23
NZ285339A (en) 1998-04-27
EP1325957A3 (en) 2003-11-26
US6013262A (en) 2000-01-11
PT1325957E (pt) 2007-01-31
ES2203640T3 (es) 2004-04-16
ATE340859T1 (de) 2006-10-15
EP0759935B1 (en) 2003-07-16
EP1325957A2 (en) 2003-07-09
EP0759935A4 (en) 1999-07-07
AUPM566794A0 (en) 1994-06-09
PT759935E (pt) 2003-11-28

Similar Documents

Publication Publication Date Title
DK0759935T3 (da) Rekombinant papillomavirus L1
NO20000850L (no) Vaksine
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
WO1999033868A3 (en) Human papillomavirus vaccine
DE69535018D1 (de) Papillomavirus vakzine
ATE326479T1 (de) Varianten von antigenen des menschlichen papillomvirus
DE69829668D1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
FR2697022B1 (fr) Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
DE69123970D1 (de) Ehv-4 glykoprotein vazin
FI113621B (fi) Menetelmä rekombinanttiadenovirusrokotteiden valmistamiseksi
DE69922212D1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek